| __timestamp | BioMarin Pharmaceutical Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 504755000 |
| Thursday, January 1, 2015 | 402271000 | 838526000 |
| Friday, January 1, 2016 | 476593000 | 1177697000 |
| Sunday, January 1, 2017 | 554336000 | 1320433000 |
| Monday, January 1, 2018 | 604353000 | 1556200000 |
| Tuesday, January 1, 2019 | 680924000 | 1834800000 |
| Wednesday, January 1, 2020 | 737669000 | 1346000000 |
| Friday, January 1, 2021 | 759375000 | 1824900000 |
| Saturday, January 1, 2022 | 854009000 | 2115900000 |
| Sunday, January 1, 2023 | 937300000 | 2631300000 |
| Monday, January 1, 2024 | 1009025000 | 2954400000 |
Unlocking the unknown
In the competitive landscape of biotechnology, operational efficiency is key. Over the past decade, Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Regeneron's SG&A expenses surged by over 400%, peaking at approximately $2.63 billion in 2023. In contrast, BioMarin's expenses grew by about 210%, reaching nearly $937 million in the same year. This disparity highlights Regeneron's aggressive expansion and investment in administrative capabilities, while BioMarin maintains a more conservative approach. The data suggests that Regeneron's strategy may be linked to its broader market reach and product diversification. As the biotech industry continues to evolve, these financial strategies will play a crucial role in shaping the future trajectories of these pharmaceutical giants.
Pfizer Inc. or Regeneron Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Gilead Sciences, Inc. or BioMarin Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. or Viatris Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Exelixis, Inc.
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG Trends and Insights
Regeneron Pharmaceuticals, Inc. or Ligand Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Novavax, Inc.
Operational Costs Compared: SG&A Analysis of GSK plc and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Biogen Inc. vs BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Bio-Techne Corporation vs BioMarin Pharmaceutical Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Axsome Therapeutics, Inc.